Receiving blood is receiving life. DIAGAST’s goal is to help healthcare professionals transmit life with the help of the best blood group determination technologies. Even though it is not always a matter of life and death, transfusion errors are never acceptable.

Over the last 30 years, DIAGAST has developed an unique expertise and know-how in the transfusion sector. Theses values allow the healthcare professionals to insure the total transfusional compatibility between receivers and donors. Thus DIAGAST has combined biology with information technology, to make its equipment evolving in parallel with the best of the new technology.

DIAGAST focuses on the following 4 strategic axes:

  Creator of tailor-made Immunohaematology solutions
Our company develops, produces and markets reagents and automated systems (QWALYS) for the blood grouping determination. Thanks to its mastering of the value chain (from R&D to the installation of solutions including customer training) DIAGAST is able to offer reliable solutions tailored to the needs and requirements of its customers.

  Innovator in biotechnologies
In a domain of activity where the last real technological innovation proposed by all of our competitors goes back to 1993, DIAGAST through its R & D department always looking for more performance and safety, features breakthrough techniques and innovates by new technologies such as EM® Technology launched in 2004 and Haem Trap launched in 2012 .

  Supplier to the major IH companies
Its large production capacity (a wide range of "FDA approved" fermentors, a portfolio of over 40 clones) and renowned and recognized know-how allow DIAGAST to provide without failing its customers but also its competitors.

  Commited to a sustainable development policy
DIAGAST promotes a CSR policy (Corporate Social Responsability) to select its suppliers, to educates its employees (eco-behaviour guide, pro-senior employment,...) and to organize events internally and externally.

DIAGAST was founded within the Centre Régional de Transfusion Sanguine (Regional Blood Transfusion Center) in Lille in 1968. Its role consisted of manufacturing reagents capable of determining blood groups for patients who needed blood transfusions, as well as for the blood used in transfusions. Later, the laboratory invented a wide range of revolutionary reagents (monoclonal reagents) for which it is the exclusive agent.

Actor from the world of biology, DIAGAST is born in 1988 thanks to the complementarity of scientists and commercial teams. The laboratory created a wide range of revolutionary reagents (monoclonal reagents) of which he is the exclusive agent. The laboratory became a company (DIAGAST) which markets these reagents to laboratories, hospitals and blood banks.

In the nineties, DIAGAST bolstered its activity in reagent manufacturing and innovated by developing practical, accurate and easy-to-use equipment for blood group determination. Nowadays, DIAGAST has established itself throughout the world.

During the first decade of this century, we progressed from the world of reagents to "reagents integrated into automatons." Our new clones, combined with more reliable instruments and more accurate software, contributed to making safer computer-aided diagnoses.

Today, DIAGAST is a privileged partner of the E.F.S (French Blood Transfusion Service), group of 8,700 people in France.

DIAGAST present and active worldwide via our network of 70 approved distributors. DIAGAST international sales currently represents 65% of the company’s sales figures. And this will increase over time because international markets are the future of our company.